Compare EOD & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EOD | VCRE |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 271.7M |
| IPO Year | N/A | 2026 |
| Metric | EOD | VCRE |
|---|---|---|
| Price | $5.98 | $10.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $24.27 |
| AVG Volume (30 Days) | ★ 112.2K | 16.6K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.94 |
| Revenue Next Year | N/A | $694.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.51 | $7.88 |
| 52 Week High | $6.74 | $14.01 |
| Indicator | EOD | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 50.38 |
| Support Level | $5.51 | $8.83 |
| Resistance Level | $6.26 | $11.78 |
| Average True Range (ATR) | 0.12 | 0.40 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 4.76 | 47.26 |
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.